Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Emergent BioSolutions (EBS) Tops Q4 EPS by 23c
February 24, 2022 4:35 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $4.50, $0.23 better than the analyst estimate of $4.27. Revenue for the quarter came in at $723.2 million versus the consensus estimate of $691.36 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More